For patients with diabetes, there have been studies showing that medical providers are less likely to prescribe certain medications to commercially insured patients who are Black, than they are to those who are white
For weight management, the Food and Drug Administration (FDA) has approved two medications: Semaglutide (Wegovy) Tirzepatide (Zepbound) These drugs contain the same active ingredients as diabetes medications such as Ozempic and Mounjaro, but Wegovy and Zepbound are specifically approved for chronic weight management
A trove of clinical trial data on how genetics influence various responses to GLP-1 receptor agonists, including weight loss, likely exists, though that data has been difficult to come by
One major study called the FLOW trial found that GLP-1 medications reduced kidney problems by 24 percent in people with diabetes
These medications can provide significant benefits for weight loss, diabetes management, and overall health when used appropriately
FDA Sends Warning Letters to Telehealth Companies The FDA has recently issued warnings to 30+ telehealth companies regarding the prescribing and promotion of compounded GLP-1 drugs, including semaglutide
